logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
J

Jifeng Feng

department of anesthesiology
H指数:63
被引数:3.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and safety of consolidative thoracic radiotherapy after first-line chemoimmunotherapy in patients with extensive-stage small-cell lung cancer: a retrospective cohort study

广泛期小细胞肺癌患者一线化学免疫治疗后巩固胸部放疗的疗效和安全性: 一项回顾性队列研究

TRANSLATIONAL LUNG CANCER RESEARCH
IF3.5
2024-12-010
OAAI
Zheng, Lin; Yang, Yang; Bu, Fan; Ye, Ruizhi; Zhang, Fengming; Ji, Zhixiang; Zhu, Xirong; Chen, Hong; Shao, Rongjun; Liu, Lidan; Ying, Xixi; Zhu, Lingying; Wang, Enyu; Feng, Jifeng; Shi, Zhiyong; Fang, Jun; Wang, Yuezhen; Zhou, Zhirui; You, Guangxian
CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma

CHRONOS-4: copanlisib加利妥昔单抗为基础的免疫化疗治疗复发性惰性b细胞淋巴瘤的3期研究

BLOOD ADVANCES
IF7.1
2024-09-130
OAAI
Zinzani, Pier Luigi; Wang, Huaqing; Feng, Jifeng; Kim, Tae Min; Tao, Rong; Zhang, Huilai; Fogliatto, Laura; Artigal, Clara Maluquer; Ozcan, Muhit; Yanez, Eduardo; Kim, Won Seog; Kirtbaya, Dmitry; Kriachok, Iryna; Maciel, Felipe; Xue, Hongwei; Bouabdallah, Krimo; Phelps, Charles; Chaturvedi, Shalini; Weispfenning, Anke; Morcos, Peter N.; Odongo, Fatuma; Buvaylo, Viktoriya; Childs, Barrett H.; Dreyling, Martin; Matasar, Matthew; Ghione, Paola
Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant A Randomized Clinical Trial

Ivonescimab联合化疗治疗EGFR变异的非小细胞肺癌随机临床试验

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
IF55
2024-08-209
OA
Fang, Wenfeng; Zhao, Yuanyuan; Luo, Yongzhong; Yang, Runxiang; Huang, Yan; He, Zhiyong; Zhao, Hui; Li, Mingjun; Li, Kai; Song, Qibing; Du, Xiaobo; Sun, Yulan; Li, Wei; Xu, Fei; Wang, Zhiyu; Yang, Kunning; Fan, Yun; Liu, Baogang; Zhao, Hongyun; Hu, Ying; Jia, Li; Xu, Shen; Yi, Tienan; Lv, Dongqing; Lan, Haitao; Li, Mengxia; Liang, Wenhua; Wang, Yongsheng; Yang, Hui; Jia, Yuming; Chen, Yuan; Lu, Junguo; Feng, Jifeng; Liu, Chunling; Zhou, Ming; Zhou, Jianya; Liu, Xianling; Zhou, Ningning; He, Ming; Dong, Xiaorong; Chen, Hualin; Chen, Yongxing; Su, Haichuan; Li, Xiaoling; Zhang, Zhihong; Yang, Lei; Cheng, Ying; Chen, Likun; Hou, Xue; Zhang, Yu; Guo, Jun; Wang, Zhen; Lu, Hong; Wu, Di; Feng, Weineng; Li, Wen; Huang, Jianan; Wang, Yan; Song, Xia; Peng, Jiewen; Liu, Laiyu; Guo, Yubiao; Li, Wenting; Lu, Dongmei; Hu, Mingxiu; Wang, Zhongmin Maxwell; Li, Baiyong; Xia, Michelle; Zhang, Li
Open-label, single-arm, multicenter, phase 2 trial of garsorasib in KRAS G12C-mutated non-small-cell lung cancer
CANCER RESEARCH
IF16.6
2024-04-050
PRE
Li, Ziming; Dang, Xiaomin; Huang, Dingzhi; Jin, Shi; Li, Weiwei; Shi, Jianhua; Wang, Xicheng; Zhang, Yiping; Song, Zhengbo; Zhang, Junping; Zhuang, Wu; Liu, Xuewen; Jiang, Liyan; Meng, Xiangjiao; Zhao, Mingfang; Zhou, Jianying; Zhang, Liangming; Wang, Pingli; Luo, Hui; Yang, Junquan; Cang, Shundong; Wang, Xiang; Wang, Jing; Cui, Jiuwei; Yu, Yan; Zhang, Zhihong; Lu, Junguo; Yang, Weihua; Li, Gaofeng; Feng, Jifeng; Lv, Dongqing; Wu, Lin; Fang, Yong; Wang, Yan; Zhao, Yanqiu; Cao, Baoshan; Zhu, Wei; Zhuang, Zhixiang; Li, Qingshan; Wang, Mingxi; Zhou, Huan; Dong, Xiaorong; Hu, Sheng; Fang, Jian; Zhang, Yihong; Wang, Wenjia; Xiang, Ziyong; Shi, Zhe; Zhang, Ling; Lu, Shun
Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case report and literature review

tislelizumab联合化疗治疗转移性三阴性乳腺癌的最佳反应: 病例报告和文献复习

FRONTIERS IN ONCOLOGY
IF3.3
2024-03-280
OAAI
Ma, Yuxin; Shi, Xinhong; Zhao, Kun; Hu, Shuyi; Shi, Yue; Jiang, Yingying; Liu, Yiling; Lu, Lin; Chang, Yuting; Zhou, Fei; Dai, Yingying; Wu, Zipeng; Li, Shiyi; Qian, Zhiying; Xu, Xia; Li, Chenchen; Shen, Bo; Zhou, Guoren; Chen, Cheng; Wang, Xiaohua; Feng, Jifeng
A real-world observation on thrombopoietic agents for patients with cancer treatment-induced thrombocytopenia in China: A multicenter, cross-sectional study
CANCER
IF5.1
2024-03-221
OAAI
Chen, Meiting; Li, Lu; Xia, Qing; Chen, Xiaobing; Liao, Zijun; Wang, Chang; Shen, Bo; Zhou, Min; Zhang, Qingyuan; Zhang, Yanqiao; Qian, Liting; Yuan, Xianglin; Wang, Zhehai; Xue, Cong; An, Xin; Liu, Bin; Gu, Kangsheng; Hou, Mei; Wang, Xiaojia; Wang, Wei; Li, Enxiao; Zhong, Jincai; Cheng, Jing; Shu, Yongqian; Yang, Nong; Wang, Huaqing; Yang, Runxiang; Liu, Tianshu; Deng, Ting; Ma, Fei; Liao, Wangjun; Qiu, Wensheng; Chen, Yu; Chen, Xi; Zhang, Mingzhi; Xu, Ruilian; Li, Xiaoling; Feng, Jifeng; Ba, Yi; Shi, Yanxia
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study
CANCER COMMUNICATIONS
IF24.9
2024-02-291
OAAI
Zheng, Jing; Wang, Tao; Yang, Yunpeng; Huang, Jie; Feng, Jifeng; Zhuang, Wu; Chen, Jianhua; Zhao, Jun; Zhong, Wei; Zhao, Yanqiu; Zhang, Yiping; Song, Yong; Hu, Yi; Yu, Zhuang; Gong, Youling; Chen, Yuan; Ye, Feng; Zhang, Shucai; Cao, Lejie; Fan, Yun; Wu, Gang; Guo, Yubiao; Zhou, Chengzhi; Ma, Kewei; Fang, Jian; Feng, Weineng; Liu, Yunpeng; Zheng, Zhendong; Li, Gaofeng; Wang, Huijie; Cang, Shundong; Wu, Ning; Song, Wei; Liu, Xiaoqing; Zhao, Shijun; Ding, Lieming; Selvaggi, Giovanni; Wang, Yang; Xiao, Shanshan; Wang, Qian; Shen, Zhilin; Zhou, Jianya; Zhou, Jianying; Zhang, Li
Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study
BMC CANCER
IF3.4
2024-01-245
OAAI
Qin, Yan; Song, Yongping; Wang, Dong; Bai, Ou; Feng, Jifeng; Sun, Xiuhua; Qiu, Lihua; Yang, Jianmin; Yang, Yu; Wang, Zhao; Hu, Jianda; Wang, Huaqing; Su, Hang; Jin, Zhengming; Qian, Wenbin; Jin, Chuan; Zhang, Mingzhi; Yu, Ding; Liu, Li; Chen, Guoan; Li, Yarong; Sun, Tao; Jin, Jie; Bao, Huizheng; Du, Xin; Zhou, Hui; Fu, Gan; Shi, Yuankai
Therapeutic effectiveness of anlotinib combined with etoposide in extensive-stage small-cell lung cancer: a single-arm, phase II trial

安洛替尼联合依托泊苷治疗广泛期小细胞肺癌的疗效: 一项单臂II期试验

INVESTIGATIONAL NEW DRUGS
IF2.7
2023-10-141
OAAI
Wu, Yuan; Zhou, Xuefeng; Zhao, Weiqing; Wang, Qiong; Han, Zhengxiang; Wang, Lifeng; Zhou, Wenjie; Zhou, Tong; Song, Haizhu; Chen, Yong; Yang, Kaihua; Shi, Lin; Pan, Banzhou; Guo, Renhong; Zhou, Guoren; Jiang, Feng; Feng, Jifeng; Shen, Bo
Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double- blind, placebo-controlled, phase 3 trial
ACTA PHARMACEUTICA SINICA B
IF14.6
2023-05-0116
OAAI
Xu, Binghe; Zhang, Qingyuan; Hu, Xichun; Li, Qing; Sun, Tao; Li, Wei; Ouyang, Quchang; Wang, Jingfen; Tong, Zhongsheng; Yan, Min; Li, Huiping; Zeng, Xiaohua; Shan, Changping; Wang, Xian; Yan, Xi; Zhang, Jian; Zhang, Yue; Wang, Jiani; Zhang, Liang; Lin, Ying; Feng, Jifeng; Chen, Qianjun; Huang, Jian; Zhang, Lu; Yang, Lisong; Tian, Ying; Shang, Hongyan
Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive/human epidermal growth factor receptor 2-advanced breast cancer (FRIEND study)

氟维司坦与依西美坦一线治疗中国绝经后雌激素受体阳性/人表皮生长因子受体2-晚期乳腺癌的临床疗效 (FRIEND研究)

EUROPEAN JOURNAL OF CANCER
IF7.1
2023-05-018
PRE
Wang, Jiayu; Cai, Li; Song, Yanqiu; Sun, Tao; Tong, Zhongsheng; Teng, Yuee; Li, Huiping; Ouyang, Quchang; Chen, Qianjun; Cui, Shude; Yin, Yongmei; Liao, Ning; Sun, Qiang; Feng, Jifeng; Wang, Xiaojia; Xu, Binghe

研究方向

暂未获取到该数据
W
Wu, Jianzhong
H 指数:0论文数:36被引数:0
R
Rong Ma
H 指数:27论文数:195被引数:2,544
Q
Qingyuan Zhang
H 指数:39论文数:220被引数:5,363
徐兵河 封面图
徐兵河
H 指数:63论文数:785被引数:2.8万
X
Xiaojia Wang
H 指数:34论文数:288被引数:8,179
S
Siwen Liu
H 指数:16论文数:48被引数:844
程
程颖
H 指数:84论文数:1,042被引数:4.4万
Z
Zhongsheng Tong
H 指数:31论文数:220被引数:4,919
S
Shaorong Yu
H 指数:21论文数:95被引数:1,792
J
Junying Zhang
H 指数:30论文数:225被引数:4,624